To test the preventive ability of vaccines co-targeting HER2/neu and IGF1R, we used p53 knockout, HER2/neu transgenic BALB/c male mice (BALB-p53Neu), which develop at early age HER2/neu-driven, IGF1R-dependent pelvic rhabdomyosarcoma, along with salivary carcinoma [22,29,30]. Here, ERBB2 is linked to salivary gland carcinoma.